Direct medical costs of using enzalutamide or abiraterone in chemotherapy-naïve patients with metastatic castration resistant prostate cancer
Introduction. A number of drugs, which improve overall survival and quality of patients' life, became available for treatment of metastatic castration-resistant prostate cancer (mCRPC). enzalutamide and abiraterone are the only two hormonal drugs increasing survival and approved for the treatme...
Salvato in:
| Autori principali: | , , |
|---|---|
| Natura: | Libro |
| Pubblicazione: |
IRBIS LLC,
2019-01-01T00:00:00Z.
|
| Soggetti: | |
| Accesso online: | Connect to this object online. |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
|
Accesso online
Connect to this object online.3rd Floor Main Library
| Collocazione: |
A1234.567 |
|---|---|
| Copia 1 | Disponibile |